AMCP Leading the way to help patients get the medications they need at a cost they can afford. Join Us Close
Medicare Part D
(46 Results)

Fraud, Waste and Abuse in the Medicare Part D Prescription Drug B...

Where We Stand: Find out about Fraud, Waste and Abuse in the Medicare Part D Prescription Drug Benefit.

5/20/19

AMCP Submits Comments to CMS on Advance Notice of Methodological ...

On March 1, 2019, AMCP provided comments to CMS in response to its 2020 for Medicare Part D Call Letter. AMCP offered comments on the following sections of the notice; Part D Benefit Parameters for Non-Defined Standard Plans; Formulary Submissions; Medication Therapy Management (MTM); and Part D Mail Order Auto-Ship Modifications.

3/1/19

Implications for Managed Care Pharmacy from the 2020 Medicare Par...

AMCP webinar that reviewed the provisions contained in the draft 2020 CMS Medicare Part D Call Letter that was released by the Centers for Medicare and Medicaid Services (CMS) on January 30, 2019.

2/20/19

AMCP Summary: Fraud and Abuse; Removal of Safe Harbor Protection ...

On January 31, 2019, HHS proposed sweeping changes to the current system for medication pricing and contracting by PBM companies in federal programs. This summary reviews OIG's proposal to eliminate the safe harbor protections for rebates that exist in the federal Anti-Kickback Statute (AKS) and replace these protections with proposed new safe harbors allowing for point-of-sale discounts to beneficiaries and for manufacturer-paid service fees to PBMs.

1/31/19

AMCP Summary: 2018 Draft Call Letter

On January 30, 2019, CMS published an Advanced Notice of Methodological Changes for Calendar Year 2020 for Medicare Advantage Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter. The summary outlines proposals in the draft Call Letter.

1/30/19

AMCP Submits Comments to CMS on Medicare and Medicaid Programs; R...

On January 25, 2019, AMCP provided comments to CMS in response to its proposed rule on lowering drug prices and reducing out-of-pocket expenses in the Medicare program. The letter outlines the proposal’s impact on providing plan flexibility to manage protected classes, prohibition against gag clauses in pharmacy contracts, E-Prescribing and the Part D Prescription Drug Program, Part D explanation of benefits, and Medicare Advantage and step therapy in Part B.

1/25/19

AMCP Submits Comments to CMS on Modernizing Part D and Medicare A...

On January 25, 2019, AMCP provided comments to CMS in response to the proposed rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses. AMCP offered comments on the following CMS proposals; Providing Plan Flexibility to Manage Protected Classes; Prohibition Against Gag Clauses in Pharmacy Contracts; E-Prescribing and the Part D Prescription Drug Program; Updating Part D E-Prescribing Standards; Part D Explanation of Benefits; and Medicare Advantage and Step Therapy for Part B Drugs.

1/25/19